ArticleEMBO reports2026
Relevance of the antibody Fc fragment and epitope valency in protection against malaria sporozoites.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Protection against infection by Plasmodium falciparum sporozoites is mediated in part by antibodies that recognize the repeated (NPNA)3 epitopes of the circumsporozoite protein (CSP). To evaluate the role that the antibody Fc region plays in neutralizing sporozoite infectivity, we assess the protective efficacy of Fab fragments obtained from protective human monoclonal antibodies and use antibodies bearing the LALA and KA mutations known to reduce Fc functions. To determine the impact of multiple-antibody binding to CSP on protection, we use sporozoites from genetically modified P. berghei strains expressing a CSP containing different numbers of (NPNA)3 epitopes. Our results indicate that Fab fragments and Fc-mutated antibodies have a protective efficacy comparable to intact antibodies, indicating a limited role, if any, of Fc functions in sporozoites in this model system. We also determine that antibody binding to multiple adjacent epitopes and the establishment of homotypic interactions between bound antibodies may not be necessary for protection, as binding to one epitope is sufficient to strongly reduce liver burden while only two separate epitopes are needed to achieve sterile protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.